In this episode of Back Bay’s industry podcast, The Life Science Report, Dr. Peter Bak is joined by Mike Bogetofte Barnkob, a doctor with the Department of Clinical Immunology at Odense University Hospital in Denmark and a research fellow at the University of Southern Denmark, to discuss current perspectives—clinical, scientific and manufacturing—on the cell therapy space.
Show Notes
In this episode of Back Bay’s industry podcast, The Life Science Report, Dr. Peter Bak is joined by Mike Bogetofte Barnkob, a doctor with the Department of Clinical Immunology at Odense University Hospital in Denmark and a research fellow at the University of Southern Denmark, to discuss current perspectives—clinical, scientific and manufacturing—on the cell therapy space.
Dr. Barnkob’s expertise spans basic and clinical immunology, with a particular interest in advanced cellular modalities, such as chimeric antigen or CAR T-cells. He studied at the Massachusetts Institute of Technology, in Back Bay’s hometown, and completed his PhD at Oxford University.
Topics in this podcast include:
- The current clinical and academic uses of CAR T-cells and where they are headed in the near-term
- How cellular therapies factor into a robust and thriving public healthcare-based system
- Ongoing questions of pricing and reimbursement
- Challenges and approval processes in getting these "living medicines" to people
- Hurdles and considerations when building a Good Manufacturing Practice (GMP) cellular facility
Do you have a question about development in the cell therapy space? Drop Back Bay a
line.
Make sure to subscribe to our podcast and follow Back Bay Life Science Advisors on
LinkedIn.
Thank you for joining us.
What is Back Bay Life Science Report?
Back Bay Life Science Advisors brings you expert insights from our advisors and investment bankers in the world of BioPharma & MedTech. On this podcast, you’ll hear from our experts in life science development, commercialization, and investment banking, scientific investigators, biotech and medtech executives, physicians, and strategists who excel at guiding global life sciences companies and their investors through complex decisions. Join us for insights generated from in-depth scientific, strategic, and financial analysis at the intersection of science and business.